1
Return

Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification

delete2026-06-19
delete0
delete
OA
AI
N
Newsome, Philip N.
S
Sartini, Claudio
M
Morris, Heather L.
G
Gazis, Derek
M
Mospan, Andrea R.
B
Barritt, A. Sidney IV
F
Fried, Michael W.
A
Augustin, Salvador
F
Fraessdorf, Mandy
R
Rudolph, Bryan
L
Loomba, Rohit
O
on behalf of TARGET-NASH Investigators
DOI：10.1097/HC9.0000000000000962delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Recognition and management of metabolic dysfunction–associated steatohepatitis (MASH) are hindered by variability in diagnostic practices and limited real-world data on disease progression. This study assessed the use of non-invasive testing (NIT) in MASH identification and estimated incidence rates and time-to-disease progression.
Keywords:
Fibrosis-4 score
fibrosis
MASLD
non-invasive tests
TARGET-NASH

Journal

Hepatology Communications cover
Hepatology Communications
IF:
4.6
Papers:
1.9K
Citations:
6.2K

Organization

K
king's college london and foundation for liver research and king's college hospital
Scholars:
2
Papers: 1
Citations: 0
B
boehringer ingelheim
Scholars:
376
Papers: 128
Citations: 0
V
Virginia Commonwealth University
Scholars:
2.1W
Papers: 1.8W
Citations: 1.9W
U
university of california san diego
Scholars:
4.6K
Papers: 2.1K
Citations: 1
T
target rwe
Scholars:
8
Papers: 3
Citations: 0
U
University of North Carolina
Scholars:
4.2K
Papers: 1.9K
Citations: 337
Cited Papers

Cited Papers

Citing Papers

Citing Papers